Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
Serverless GPU cloud platform for AI/ML with Python-native deployment and per-second billing; developer-favorite scaling from zero competing with Replicate and Beam for AI compute.
Modal is a serverless cloud computing platform purpose-built for AI and machine learning workloads — providing on-demand GPU compute that scales instantly from zero with per-second billing, container management, distributed training support, and a Python-native developer experience that makes running ML workloads in the cloud feel as simple as running code locally. Founded in 2021 in New York City and backed by Redpoint Ventures and other investors, Modal has grown rapidly as AI development has accelerated demand for flexible, developer-friendly GPU infrastructure.\n\nModal's developer experience is its primary differentiator — engineers write Python functions decorated with @modal.function() and deploy them to the cloud with a single command, with Modal handling container building, GPU provisioning, auto-scaling, and execution. The platform supports training jobs that need distributed compute across multiple GPUs, model serving endpoints that scale to zero when unused (eliminating idle GPU costs), and batch inference jobs that process large datasets. The per-second billing model means developers pay only for actual compute time, not provisioned instances.\n\nIn 2025, Modal competes in the AI infrastructure market with Replicate, Beam, Banana, and major cloud providers' managed ML services (AWS SageMaker, Google Vertex AI, Azure ML) for serverless GPU compute. The market for AI-specific cloud infrastructure has grown dramatically as the number of ML engineers deploying models to production has expanded — traditional cloud providers require significant DevOps expertise to use GPU instances effectively, while Modal's Python-native approach reduces the barrier to entry. Modal has attracted a strong developer following among AI researchers and ML engineers building production AI applications. The 2025 strategy focuses on growing the developer community, adding enterprise features (dedicated GPU capacity, private networking, compliance), and expanding the hardware options available (H100 GPUs, custom accelerators).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.